×
Dogwood Therapeutics Common Stock Net 2020-2024 | DWTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Dogwood Therapeutics common stock net from 2020 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
Dogwood Therapeutics Common Stock Net 2020-2024 | DWTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Dogwood Therapeutics common stock net from 2020 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$174.7B
Vertex Pharmaceuticals (VRTX)
$125B
Regeneron Pharmaceuticals (REGN)
$112.1B
Bristol Myers Squibb (BMY)
$107B
Gilead Sciences (GILD)
$106.8B
CSL (CSLLY)
$97.4B
GSK (GSK)
$80.7B
Alnylam Pharmaceuticals (ALNY)
$36.9B
Argenex SE (ARGX)
$32.6B
BioNTech SE (BNTX)
$27.9B
Biogen (BIIB)
$27.9B
Illumina (ILMN)
$23.5B
Moderna (MRNA)
$22B
BeiGene (BGNE)
$21.7B
Genmab (GMAB)
$15.3B
BioMarin Pharmaceutical (BMRN)
$13.4B
Exact Sciences (EXAS)
$12.9B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
Incyte (INCY)
$12.8B
Sarepta Therapeutics (SRPT)
$11.8B
Bio-Techne Corp (TECH)
$11.7B
QIAGEN (QGEN)
$10B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.8B
Legend Biotech (LEGN)
$8.2B
Revolution Medicines (RVMD)
$8.2B
Exelixis (EXEL)
$8.1B
Repligen (RGEN)
$8.1B
Intra-Cellular Therapies (ITCI)
$7.9B